In the Prospective Comparison of ARNI (Angiotensin Receptor Neprilysin Inhibitor) with ACE inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM‐HF), the addition of neprilysin inhibition to blockade of the renin angiotensin aldosterone system (RAAS) (using sacubitril/valsartan), compared with RAAS blockade alone (using the gold‐standard ACE inhibitor enalapril), reduced the risk of HF hospitalization and cardiovascular death in patients with HFrEF.20 The gene discussed is ACE; the disease is heart failure.